Journal Watch · Proceedings of the National Academy of Sciences (PNAS) · 2026

Cannabinoid tolerance relies on CB<sub>1</sub> receptor ubiquitination by NEDD4L.

These findings reveal a molecular mechanism that controls CB<sub>1</sub>R stability and identify NEDD4L-mediated ubiquitination as a central driver of cannabinoid tolerance.

Álvaro-Blázquez A, Rodrigues RS, Montero-Fernández C et al.Proceedings of the National Academy of Sciences (PNAS)3 min readPharma relevance 50/100

DOI: 10.1073/pnas.2606671123PMID: 42640804Study type: preclinical (animal / model) study

TL;DR

These findings reveal a molecular mechanism that controls CB<sub>1</sub>R stability and identify NEDD4L-mediated ubiquitination as a central driver of cannabinoid tolerance.

Key findings

  • Using molecular, pharmacological, and circuit-specific rescue approaches, we demonstrate that preventing CB<sub>1</sub>R ubiquitination stabilizes receptor levels and abolishes behavioral cannabinoid tolerance in mice without impairing acute drug responses.
  • These findings reveal a molecular mechanism that controls CB<sub>1</sub>R stability and identify NEDD4L-mediated ubiquitination as a central driver of cannabinoid tolerance.

What they did

Here, we identify a ubiquitin-dependent pathway that couples CB<sub>1</sub>R activation to its proteasomal degradation. We show that cannabinoids engage a G<sub>q/11</sub>-PLC-PKC signaling cascade that phosphorylates and activates the E3 ubiquitin ligase neural precursor cell-expressed developmentally downregulated 4-like (NEDD4L), promoting its recruitment to CB<sub>1</sub>R and the ubiquitination of four specific lysine residues. This modification targets the receptor for proteasomal clearance, reducing neuronal CB<sub>1</sub>R abundance in vitro and in the mouse brain.

Full abstract (original)

Background: Cannabinoids, the active components of cannabis, exert numerous acute effects in the brain by engaging cannabinoid CB<sub>1</sub> receptors (CB<sub>1</sub>Rs). However, tolerance emerges rapidly after repeated drug exposure, undermining the efficacy of cannabinoid-based therapies and contributing to cannabis-associated adverse effects. Although the processes of CB<sub>1</sub>R short-term desensitization (i.e., receptor uncoupling and internalization) are well characterized, the mechanisms underlying CB<sub>1</sub>R long-term tolerance (i.e., downregulation of receptor protein levels) remain elusive.

What they did: Here, we identify a ubiquitin-dependent pathway that couples CB<sub>1</sub>R activation to its proteasomal degradation. We show that cannabinoids engage a G<sub>q/11</sub>-PLC-PKC signaling cascade that phosphorylates and activates the E3 ubiquitin ligase neural precursor cell-expressed developmentally downregulated 4-like (NEDD4L), promoting its recruitment to CB<sub>1</sub>R and the ubiquitination of four specific lysine residues. This modification targets the receptor for proteasomal clearance, reducing neuronal CB<sub>1</sub>R abundance in vitro and in the mouse brain.

Results & conclusions: Using molecular, pharmacological, and circuit-specific rescue approaches, we demonstrate that preventing CB<sub>1</sub>R ubiquitination stabilizes receptor levels and abolishes behavioral cannabinoid tolerance in mice without impairing acute drug responses. These findings reveal a molecular mechanism that controls CB<sub>1</sub>R stability and identify NEDD4L-mediated ubiquitination as a central driver of cannabinoid tolerance.

Abstract © the authors / Proceedings of the National Academy of Sciences (PNAS) (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1073/pnas.2606671123 · PubMed 42640804.

Why it matters for pharma & biotech

  • Relevant to General & Medicine teams tracking Proceedings of the National Academy of Sciences (PNAS) for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Proceedings of the National Academy of Sciences (PNAS) study find?

These findings reveal a molecular mechanism that controls CB<sub>1</sub>R stability and identify NEDD4L-mediated ubiquitination as a central driver of cannabinoid tolerance.

What type of study is this?

It is a preclinical (animal / model) study, published in Proceedings of the National Academy of Sciences (PNAS) in 2026. Here, we identify a ubiquitin-dependent pathway that couples CB<sub>1</sub>R activation to its proteasomal degradation.

Where can I read the original paper?

The original is at the publisher via DOI 10.1073/pnas.2606671123. PubMed ID: 42640804. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Álvaro-Blázquez A, Rodrigues RS, Montero-Fernández C et al.. Cannabinoid tolerance relies on CB&lt;sub&gt;1&lt;/sub&gt; receptor ubiquitination by NEDD4L.. Proceedings of the National Academy of Sciences (PNAS) (2026). DOI: 10.1073/pnas.2606671123.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/cannabinoid-tolerance-relies-on-cb-lt-sub-gt-1-lt-sub-gt-receptor-ubiqui-671123/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides